Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

BOTHELL, WA, and VANCOUVER, May 30 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced preliminary results of a Phase 1 trial presented during an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. Preliminary results as of April 2009 showed that OGX-427 was well tolerated as a monotherapy. In addition, OGX-427 demonstrated declines in circulating tumor cells at all doses evaluated as well as evidence of reduction in tumor markers. Reductions in circulating tumor cells and tumor markers both suggest single-agent activity warranting further clinical investigation.

The Phase 1 trial has evaluated 41 patients with a variety of cancers to date; enrollment is ongoing. The first phase of the study evaluated increasing doses of OGX-427 as a single agent up to 1000 mg. A maximum tolerated dose was not identified up to and including the 1000-mg dose of OGX-427 monotherapy. Subsequently, as defined by the protocol, an 800-mg dose of OGX-427 in combination with docetaxel was evaluated, to be followed by a 1000-mg dose of OGX-427 plus docetaxel. OGX-427 is administered as three loading doses within the first 9 days and then continued weekly, with three weeks defined as a treatment cycle, until disease progression or toxicity. In those groups receiving OGX-427 in combination with docetaxel, 75mg/M(2) docetaxel was administered on Day 1 of every 3-week cycle starting after completion of the OGX-427 loading doses.

Safety Results

Patients enrolled had a diagnosis of breast, ovarian, prostate or non-small cell lung cancer and most had failed multiple prior chemotherapy treatments. A median of 2 cycles (range of 1-8 cycles) was administered with the following safety results for OGX-427 as monotherapy:

    -   Criteria for a maximum tolerated dose were 
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... CAMBRIDGE, Mass. , July 14, 2014 ... in the development of new therapies to treat neuropsychiatric ... Ahlholm has been appointed vice president of finance ... Mr. Ahlholm is a senior executive with more ... functions at technology and life science companies. His background ...
(Date:7/14/2014)... July 14, 2014 PatientCrossroads, ... platform, announced that three PatientCrossroads-based patient registries—DuchenneConnect, ... Phelan-McDermid Syndrome International Registry; and the NephCure ... awarded contracts by the Patient-Centered Outcomes Research ... of a new health data network called ...
(Date:7/13/2014)... discovery 30 years ago of soccer-ball-shaped carbon molecules called ... Now, there appears to be a new ball on ... and Tsinghua University in China have shown that a ... cage similar to a carbon buckyball. It,s the first ... matter of speculationdoes indeed exist. , "This is the ...
(Date:7/13/2014)... 2014 Deep Research Report on Global and China ... on the current state of the Nano Silver industry ... basic overview of the industry, including definitions, applications and ... market analysis are provided with a focus on history, ... comparison between the international and Chinese situation is also ...
Breaking Biology Technology:Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3
... Proprietary Products Division of Par Pharmaceutical with Initial Focus on ... ... WOODCLIFF LAKE, N.J., Sept. 28 /PRNewswire-FirstCall/ - Par,Pharmaceutical Companies, Inc. ... marketing novel prescription drugs, through the,establishment and introduction of Strativa ...
... Mass., Sept. 28 Idenix,Pharmaceuticals, Inc. (Nasdaq: ... the discovery and development of drugs for ... a strategic restructuring. As part of the,restructuring, ... Novartis,Pharma AG related to Tyzeka(R)/Sebivo(R). Per the ...
... NORCROSS, Ga., Sept. 28 Immucor, Inc.,(Nasdaq: ... providing automated instrument-reagent,systems to the blood transfusion ... Commission (SEC) has agreed to a complete,settlement ... the company,s Italian subsidiary. Under the ...
Cached Biology Technology:Introducing Strativa Pharmaceuticals 2Introducing Strativa Pharmaceuticals 3Introducing Strativa Pharmaceuticals 4Introducing Strativa Pharmaceuticals 5Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 2Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 3Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs 4Immucor Settles SEC Investigation 2
(Date:7/14/2014)... could overcome a major cost barrier to make ... replace expensive and environmentally harmful fossil fuels. , ... performs almost as well as cost-prohibitive platinum for ... split water molecules into hydrogen and oxygen. The ... less-expensive catalysts investigated to-date. , "Hydrogen has long ...
(Date:7/14/2014)... to reliably and safely make in the laboratory all of ... key step closer to reality. , Writing today in the ... of Wisconsin-Madison stem cell researcher Igor Slukvin reports the discovery ... and turning them into both red and the array of ... is important because it identifies how nature itself makes blood ...
(Date:7/13/2014)... women suggests that experiencing one or more stressful events ... slow the body,s metabolism, potentially contributing to weight gain. ... stressors before giving them a meal consisting of 930 ... measured their metabolic rate how long it took ... took measures of blood sugar, triglycerides, insulin and the ...
Breaking Biology News(10 mins):Rutgers chemists develop technology to produce clean-burning hydrogen fuel 2Wisconsin scientists find genetic recipe to turn stem cells to blood 2Wisconsin scientists find genetic recipe to turn stem cells to blood 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4
... that clean water and air are signs of a healthy ... the environment is right beneath their feet, according to a ... maintaining a clean environment by serving as a natural water ... and soil hydrology. Understanding the components that make up this ...
... State of the Union address, President Obama singled out climate ... can choose to believe that Superstorm Sandy, and the most ... have ever seen were all just a freak coincidence," he ... judgment of science and act before it,s too late." ...
... shift in U.S. demographics and importance of minorities took ... those growing toward majority acquire representation in our educational ... and move minorities forward to majorities in science, technology, ... gaining traction, said Castillo-Chavez, one of a trio of ...
Cached Biology News:Key to cleaner environment may be right beneath our feet 2Going negative: Stanford scientists explore new technologies that remove atmospheric CO2 2Going negative: Stanford scientists explore new technologies that remove atmospheric CO2 3Going negative: Stanford scientists explore new technologies that remove atmospheric CO2 4Going negative: Stanford scientists explore new technologies that remove atmospheric CO2 5Mentoring models to move minorities to majorities in STEM 2Mentoring models to move minorities to majorities in STEM 3
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
... HDAC8 Regulation of gene expression ... as DNA methylation, ATP-dependent chromatin remodeling, ... which include the dynamic acetylation and ... residues present in the tail of ...
...
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
Biology Products: